News

An experienced dermatologist blinded to clinical data performed the NVC using a videocapillaroscope VideoCap 3.0 (DSMedica) at 200× magnification in the study.

Intergalactic Therapeutics, based in Cambridge, MA, announced its closing after less than 2 years since the company's launch in 2021.

Veena Raiji, MD, MPH, spoke with our team about long-term outcomes of eyes requiring IOP-lowering medication in the PALADIN trial at the 2023 ASRS annual meeting.

Choroideremia shares traits with retinitis pigmentosa (RP). Both diseases are caused by underlying inherited gene defects and result in the death of photoreceptors within the retina.

J. Fernando Arevalo, MD, PhD, FACS, FASRS, a member of Modern Retina's editorial advisory board, spoke with us about clinical characteristics of macular holes that close without surgery.

The investigators explored the effects of the following covariates on development of AMD: sex, ethnicity, smoking history, fluoxetine use, obesity, diabetes mellitus, and hypertension.

In addition to the educational offerings, the program offers opportunities for relaxation and spiritual and family-building events.

Of the 484 hospitals, 22 are named to the national Honor Roll for ranking in one or more of the specialties that US News evaluates.

At the 2023 ASRS annual meeting in Seattle, Washington, Michael Singer, MD, spoke with our team about the Starlight Study, which is an optogenetic study looking at patients who had Stargardt disease.

OSC-01 is a novel, high concentration preservative-free topical OPTIREACH formulation of dexamethasone.

Aleksandra Rachiskaya, MD, a member of the Modern Retina advisory board, spoke with our team about time to fluid control with faricimab arms complete compared to aflibercept in recent studies at the 2023 ASRS annual meeting.

The Summit will inspire and enable attendees to achieve their goals via a multi-pronged approach.

According to the company, the solution slowed the loss of photoreceptors and disease progression as early as six months.

Nancy Lurker, Executive Vice-Chair of the Board of EyePoint Pharmaceuticals, discussed the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901 with our team at the 2023 ASRS annual meeting.

Prevent Blindness has declared the month of August Children’s Eye Health and Safety Month. The goal of this initiative is to educate parents and caregivers on ways to keep children’s eyes healthy.

Paul Hahn, MD, PhD, shared insights on research comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy presented at the 2023 ASRS annual meeting.

The program was created based on direct requests to CHCP by local employers, led by UT Southwestern Medical Center, who noted a high need for skilled ophthalmology assistants.

President and CEO at Outlook Therapeutics, Russ Trenary, shared an update on the company's work toward FDA approval for Bevacizumab with our team at the 2023 ASRS annual meeting.

Megan Baldwin, PhD, CEO and Managing Director of Opthea Limited, spoke with our team about the company's clinical trial drug OPT-302 (sozinibercept) at the 2023 ASRS annual meeting.

The main finding was that the male grand round attendees were more likely to pose 1 of the first 3 questions compared with female attendees.

Apellis Pharmaceuticals, Inc. presented results from the GALE extension study at the 2023 ASRS annual meeting in Seattle. The results indicated that continuous treatment with SYFOVRE (pegcetacoplan injection) for 30 months continued to show increasing beneficial effects.

Tarek Hassan, MD, spoke with our team about a novel glyco-mimetic nanoparticle, Aviceda AVD-104, being developed for the treatment of geographic atrophy.

At the 2023 ASRS annual meeting in Seattle, Washington, Ursula Schmidt-Erfurth, MD, spoke with our team to share information on the GALE extension study.

The Modern Retina team caught up with one of our board members, Fernando Arevalo, MD, PhD, FACS, FASRS, who shared information on his presentation on the treatment of progressively symptomatic retinal detachments associated with retinoschisis cases at the 2023 ASRS annual meeting.

At the 2023 ASRS annual meeting, Dante Pieramici, MD, spoke with our team to share information on OPT-302, or sozinibercept, for the treatment of neovascular AMD and other retinal vascular diseases.

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended.

Shawn Kavoussi, MD, shared insights from his research on using infrared video for vitreous opacities and comparing postoperative reduction in vitreous opacity scores using infrared video with the Heidelberg spectralis unit.

Matthew R. Starr, MD, discusses how secondary lens techniques have changed over time.

Durga Borkar, MD, MMCi, joined our team to discuss the FARETINA-DME study At the 2023 ASRS meeting in Seattle, Washington.

Richard B. Rosen, MD, shared insights from his presentation from ASRS 2023 on "New 'MacGyver-inspired' endolaser option for chandelier-assisted scleral buckles" with Sheryl Stevenson, our Group Editorial Director.